Gland Pharma Q1 FY27: Revenue Up 20% to ₹18,003 Million, PAT Grows 47%
Gland Pharma's Q1 FY27 revenue rose 20% YoY to ₹18,003 million. PAT grew 47% to ₹3,170 million. CDMO and B2B segments each contributed 50% of revenue. The company signed a strategic manufacturing deal with potential USD 90-100 million revenue from 2029.
The announcement details significant financial growth, strategic long-term agreements with substantial revenue potential, and expansion plans, all of which are material to investors and the company's future performance.
The company reported strong year-on-year growth in revenues, EBITDA, and profit after tax, driven by robust performance across its business segments and key geographic markets. Strategic partnerships and capacity expansion plans indicate positive future outlook.
Gland Pharma Limited has reported a strong start to fiscal year 2027, with Q1 FY27 revenues reaching ₹18,003 million, a 20% year-on-year increase. Adjusted EBITDA stood at ₹5,102 million (28% margin), and profit after tax (PAT) grew by 47% to ₹3,170 million (18% PAT margin).
The company's performance was driven by its CDMO and B2B businesses, which contributed 50% each to the total revenue, growing by 20% and 19% year-on-year respectively. Growth was fueled by new product launches, increased volumes, improved capacity utilization, and operational efficiencies.
The United States market remained the largest, with revenues growing 32% year-on-year to ₹9,810 million, supported by new product launches and volume expansion. Europe and other regulatory markets saw an 11% year-on-year revenue growth to ₹4,488 million. Rest of the world markets were broadly in line with the previous year at ₹3,039 million, though impacted by supply disruptions in Saudi Arabia.
Key strategic developments include a manufacturing and supply agreement with a leading global pharmaceutical company for sterilized injectables, with an expected revenue potential of USD 90-100 million starting from calendar year 2029. A collaboration with Neuland Laboratories for sterile APIs for microparticle depot products was also announced. Additionally, an in-licensing agreement with a China-based company for a niche liposomal product is expected to contribute meaningful revenue from FY30.
Investments in capacity expansion are ongoing, with multiple brownfield and greenfield initiatives across the manufacturing network. R&D spending for Q1 FY27 was ₹772 million (4% of consolidated revenue). In Europe, Cenexi reported EUR 48 million in revenue and EUR 2 million in EBITDA. The Fontenay facility will see a new ampoule line operational by early 2027, adding 30 million ampoules of annual capacity. The Hérouville and Braine-l'Alleud facilities also showed steady progress and new business wins.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.